Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

<< Previous

Bullboard Posts

Next >>

Post by SundayMovieson Mar 17, 2023 12:41pm

222 Views

Post# 35345316

ONCY valuation is of a PII biotech... undervalued

Not sure why market is still valuing ONCY as an early PII biotech.

Interim data should move this one closer to a PIII valuation - i.e. at least 250 USD milllions.

Anyway, ASCO is schedule for 1st week of June
So, we have about 2 1/2 months to wait...
As soon as we get confirmation that ONCY is going to ASCO we rocket much higher. Because if they go to ASCO it means that the results are ready and stellar.

<< Previous

Bullboard Posts

Next >>

10 best-performing AI stocks for Canadian investors